Clinical Trials
52 trialsPOPLIN
Regeneron Pharmaceuticals
MagnetisMM15
Pfizer
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Johnson & Johnson Private Limited
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Takeda
BLOOD-dose
Rigshospitalet, Denmark
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Emory University
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
CHUQUL_HO001
CHU de Quebec-Universite Laval
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Plan Development for Giving Teclistamab in the Outpatient Setting
University Health Network, Toronto
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
University of Turin, Italy
Home Based Daratumumab Administration for Patients With Multiple Myeloma
Thomas Jefferson University
VRd MM Fibrate
Tanta University
SCILLA
Odense University Hospital
Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)
National Taiwan University Hospital
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
The First Affiliated Hospital of Soochow University
POMAlternative
Amsterdam UMC, location VUmc
BE-Dasatinib
Centro de Atencion e Investigacion Medica
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
Johnson & Johnson Private Limited
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
Peking Union Medical College Hospital
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
CASI Pharmaceuticals (China) Co., Ltd.
IFM-01-04
Centre Hospitalier Universitaire de Nice
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
Pharmacosmos A/S
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Magnolia
Odense University Hospital
Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
Peking Union Medical College Hospital
US MM-7
Takeda
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
Peking Union Medical College Hospital
Z-MARK
Novartis
AZABACHE
PETHEMA Foundation
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Columbia University
PDD vs PAD to Treat Initially Diagnosed MM
The First Affiliated Hospital of Soochow University
Velcadito
Basque Health Service
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Dana-Farber Cancer Institute
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
Shandong Provincial Hospital
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
FREE Study - Fracture Reduction Evaluation
Medtronic Spinal and Biologics
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Novartis
MM
Merit Medical Systems, Inc.
A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
Johnson & Johnson Taiwan Ltd
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
Novartis
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
Swedish Orphan Biovitrum
A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
Peking University People's Hospital
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Novartis
TaCyDexVMP7
PETHEMA Foundation
A Multiple Myeloma Trial in Patients With Bone Metastases
Novartis